Monografías docentes Glucagón y la hipótesis bihormonal de la diabetes
Referencias bibliográficas
Kimball C, Murlin J. (1923). Aqueous extracts of pancreas. III. Some precipitation reactions of insulin. J Biol Chem 58: 337–348.
Sutherland EW, Cori CF, Haynes R, Olsen NS. (1949). Purification of the hyperglycemic-glycogenolytic factor from insulin and from gastric mucosa. J. Biol. Chem.180: 825–837.
Bromer WW, Sinn LG, Staub A, Behrens OK. (1957). The amino acid sequence of glucagon. Diabetes 6: 234–238.
Unger RH, Eisentraut AM, Mc CM, Keller S, Lanz HC, Madison LL. (1959). Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med 102: 621–623.
Baum J, Simons BE, Jr, Unger RH, Madison LL. (1962). Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics. Diabetes. 11: 371–374.
Muller WA, Faloona GR, Unger RH. (1973). Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 54: 52–57.
Cherrington AD, Williams PE, Shulman GI, Lacy WW. (1981). Differential time course of glucagon’s effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes. 30: 180–187.
De Castro JM, Paullin SK, DeLugas GM. (1978). Insulin and glucagon as determinants of body weight set point and microregulation in rats. J Comp Physiol Psychol 92: 571–579.
Doi K, Kuroshima A. (1982). Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats. Life Sci 30: 785–791.
Hayashi Y, Seino Y. (2018). Regulation of amino acid metabolism and α-cell proliferation by glucagon. J Diabetes Investig. 9: 464–472.
Paloyan E, Harper PV Jr. (1961). Glucagon as a regulating factor of plasma lipids. Metabolism 10: 315–323.
Lucchesi BR. (1968). Cardiac actions of glucagon. Circ Res 22: 777–787.
Campbell JE, Drucker DJ. (2015). Islet alpha cells and glucagon– critical regulators of energy homeostasis. Nat Rev Endocrinol 11: 329–338.
Arstila AU, Trump BF. (1968). Studies on cellular autophagocytosis. The formation of autophagic vacuoles in the liver after glucagon administration. Am J Pathol. 53: 687–733.
Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. (2006). The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 103: 2334–2339.
Schroeder WT, Lopez LC, Harper ME, Saunders GF (1984). Localization of the human glucagon gene (GCG) to chromosome segment 2q36–37 Cytogenet. Cell Genet. 38: 76–79.
Sandoval DA, D’Alessio DA. (2015). Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 95: 513–548.
Quesada I, Tuduri E, Ripoll C, Nadal A. (2008). Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 199: 5–19.
Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB. (2005). Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54: 1808–1815.
Yoshimoto Y, Fukuyama Y, Horio Y, Inanobe A, Gotoh M, Kurachi Y (1999). Somatostatin induces hyperpolarization in pancreatic islet alpha cells by activating a G protein-gated K+ channel. FEBS Lett 444: 265–269.
Goldenbrg D, Santos JL, Hodgson MI, Cortes VA. (2014). Nuevas proyecciones fisiológicas, patológicas y terapéuticas de la leptina. Rev. méd. Chile. 142: 738-747.
Taborsky GJ, Mundinger TO. (2012). Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 153: 1055–1062.
Gerich JE, Langlois M, Schneider V, Karam JH, Noacco C. (1974). Effects of alternations of plasma free fatty acid levels on pancreatic glucagon secretion in man. J Clin Invest 53: 1284–1289.
Bollheimer LC, Landauer HC, Troll S, Schweimer J, Wrede CE, Scholmerich J, Buettner R. (2004). Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 53: 1443–1448.
Ohneda A, Parada E, Eisentraut AM, Unger RH. (1968). Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest 47: 2305–2322.
Jones BJ, Tan T, Bloom SR. (2012). Minireview: Glucagon in Stress and Energy Homeostasis Endocrinology 153: 1049–1054.
Gerich JE. (1981). Physiology of glucagon. Int Rev Physiol 24: 243-275.
Svoboda M, Tastenoy M, Vertongen P, Robberecht P. (1994). Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol 105: 131–137.
Kieffer TJ, Heller RS, Unson CG, Weir GC, Habener JF. (1996). Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137: 5119–5125.
Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA. (1993). Expression cloning and signaling properties of the rat glucagon receptor. Science 259: 1614–1616.
Altarejos JY, Montminy M. (2011). CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12: 141–151.
Jiang G, Zhang BB. (2003). Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671–E678.
Perea A, Clemente F, Martinell J, Villanueva-Penacarrillo ML, Valverde I. (1995). Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res 27: 372–375.
Brown NF, Salter AM, Fears R, Brindley DN. (1989). Glucagon, cyclic AMP and adrenaline stimulate the degradation of low-density lipoprotein by cultured rat hepatocytes. Biochem J 262: 425–429.
Foster DW, McGarry JD. (1982). The regulation of ketogenesis. Ciba Found Symp 87: 120–131.
Takiguchi M, Mori M. (1995). Transcriptional regulation of genes for ornithine cycle enzymes. Biochem. J. 312:649–659.
Solloway MJ, Madjidi A, Gu C, Eastham-Anderson J, Clarke HJ, Kljavin N, Zavala-Solorio J, Kates L, Friedman B, Brauer M, Wang J, Fiehn O, Kolumam G, Stern H, Lowe JB, Peterson AS, Allan BB. (2015). Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of α-cell mass. Cell Rep. 12: 495–510.
Listed NA. (1969). Glucagon and the heart. Br Med J 4: 635.
Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. (2017). The new biology and pharmacology of glucagon. Physiol Rev 97: 721–766.
Muller WA, Faloona GR, Unger RH. (1973). Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med. 54: 52–57.
Raskin P, Unger RH. (1978). Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med. 299: 433–436.
Holst JJ, Holland W, Gromada J, Lee Y, Unger RH, Yan H, Sloop KW, Kieffer TJ, Damond N, Herrera PL. (2017). Insulin and Glucagon: Partners for Life. Endocrinology. 158: 696–701.
Unger RH, Cherrington D. (2012). Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 122: 4–12.
Unger RH, Orci L. (1981). Glucagon and the α cell-physiology and pathophysiology-(first of two parts). N Engl J Med. 304:1518-1524.
Scott RV, Bloom SR. (2018). Problem or solution: The strange story of glucagon. Peptides. 100: 36–41.
Buse JB, Weyer C, Maggs DG. (2002). Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes. 20: 137–144.
Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR, Wenner BR, Bain JR, Charron MJ, Newgard CB, Unger RH. (2010). Leptin therapy in insulin deficient type I diabetes. Proc Natl Acad Sci USA. 107: 4813-4819.
González-Mujica F. (2016) Drogas antidiabéticas diferentes de la insulina. Mecanismos de acción. Vitae, Abril-Junio Nº 66. Disponible en: http://vitae.ucv.ve/?module=articulo&rv=124&n=5316.
Lima-Martínez MM, Betancourt L, Bermúdez A. (2011). Glucagón: ¿un simple espectador o un jugador clave en la fisiopatología de la diabetes? Av Diabetol. 27: 160---167.
Tschop MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Muller TD, DiMarchi RD. (2016). Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24: 51–62.
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit
